• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Target Insights >Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding
【24h】

Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding

机译：针对人类免疫缺陷病毒1型组装，成熟和萌芽

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The targets for licensed drugs used for the treatment of human immunodeficiency virus type 1 (HIV-1) are confined to the viral reverse transcriptase (RT), protease (PR), and the gp41 transmembrane protein (TM). While currently approved drugs are effective in controlling HIV-1 infections, new drug targets and agents are needed due to the eventual emergence of drug resistant strains and drug toxicity. Our increased understanding of the virus life-cycle and how the virus interacts with the host cell has unveiled novel mechanisms for blocking HIV-1 replication. This review focuses on inhibitors that target the late stages of virus replication including the synthesis and traffi cking of the viral polyproteins, viral assembly, maturation and budding. Novel approaches to blocking the oligomerization of viral enzymes and the interactions between viral proteins and host cell factors, including their feasibility as drug targets, are discussed.
机译：用于治疗1型人类免疫缺陷病毒（HIV-1）的许可药物的靶标仅限于病毒逆转录酶（RT），蛋白酶（PR）和gp41跨膜蛋白（TM）。尽管目前批准的药物可有效控制HIV-1感染，但由于最终会出现耐药菌株和药物毒性，因此需要新的药物靶标和药物。我们对病毒生命周期以及病毒如何与宿主细胞相互作用的深入了解揭示了阻断HIV-1复制的新颖机制。这篇综述集中在针对病毒复制后期的抑制剂，包括病毒多蛋白的合成和运输，病毒装配，成熟和出芽。讨论了阻止病毒酶低聚以及病毒蛋白与宿主细胞因子之间相互作用的新方法，包括它们作为药物靶标的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号